Trust & Proof: REVLIMID (Bristol Myers Squibb) – Signal Evidence & AI Readability

REVLIMID (Bristol Myers Squibb)

(https://revlimid.com) 📸 Data Snapshot: June 19, 2026
Trust & Proof — The Lens

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Trust & Proof Verifiable evidence vs. Trust Theatre.
19 Impact Weight: 20 / 100
95% Reputation

Trust theatre is not present in a marketing sense; the site uses high-authority proof paths. Instead of unverified reviews, the site links to the ‘Full Prescribing Information’ and ‘FDA MedWatch.’ While a review_count of 17 is detected in the data, it is not used as a primary trust signal on the frontend, which instead relies on the ‘Lenalidomide REMS’ program and Bristol Myers Squibb corporate backing.

Proof density is high. Across all pages, the site provides a nearly 1:1 ratio of drug name mentions to regulatory warnings or proof links. Verifiable evidence includes the specific FDA-approved indications for mantle cell lymphoma and myelodysplastic syndromes, backed by the mandatory REMS program and prescribing information documents.

Trust & Proof is read by weighing trust language against real verification. Below is the page-by-page tally of review mentions and external proof links, then the schema markup that may (or may not) declare verifiable ratings and identity proof.

🛡️ Trust Signals — reviews, proof links, trust-theatre check
68Review mentions (all pages)
4External proof links (all pages)
PageReviewsProof links
/ (home) 17 1
/multiple-myeloma/ 17 1
/mds/ 17 1
/mcl/ 17 1
🔗 Identity & Technical Layer — schema JSON-LD: declared ratings, reviews & identity proof
Homepage — no schema detected (entity gap)
/multiple-myeloma/ — no schema detected (entity gap)
/mds/ — no schema detected (entity gap)
/mcl/ — no schema detected (entity gap)
Explore the other reputation pillars for REVLIMID (Bristol Myers Squibb)